Discussion
Long-term use of the approved infusion therapy Uplizna (inebilizumab) leads to lasting cuts in flares, or periods of symptom worsening, in adults with active IgG4-related disease (IgG4-RD). That’s according to the first year of data from an open-label extension (OLE) portion of the Phase 3 MITIGATE clinical…
